part of the Oct 14 PR
HUBBARD, Ohio--(BUSINESS WIRE)--
NanoLogix Inc. (NNLX), an innovative biotechnology company in Northeastern Ohio announces that it is configuring its N-Assay Rapid diagnostic kits for both Ebola Virus and Enterovirus detection and identification. NanoLogix CEO Bret Barnhizer stated, “The Company has been aware of the virus detection capabilities of the technology since the N-Assay development. Viruses viewed as public health concerns prior to Ebola and Enterovirus were Influenza, the common cold, and HIV, none of which have an immediate or near-immediate threat of mortality. Until recently, NanoLogix has been focused solely on the use of their N-Assay kit for bacteria detection and identification. Now, with the recent outbreaks of both Ebola and Enterovirus there is an immediate need for configuration of the N-Assay for viruses. NanoLogix facilities are not designed for work on viruses, for this specific project we are seeking a corporate partner with the facilities necessary to bring the new N-Assay (V) to the market as quickly as possible. We consider this a matter of national security and an emergency priority. We are in discussions with potential partners, positioned with strong ties to the US government, who understand the serious threat these viruses represent.”
the biotech world is outside my normal frame of reference and has its own set of exigencies-e.g., may have a speeded up jv process due to "national security and an emergency priority' considerations.
Also when I speak of 18 months,that includes an initial period of time when companies come to each others attention-often without direct contact- they often know the companies in their field but may not know startup companies-and usually do their own private getting to know dd of the other company BEFORE even making a decision to approach the other company (think of the reasons why this is so-including cloak and dagger/MI-6 )-and remember we are still doing dd on NNLX after many years but without the monetary resources etc often employed by companies in their dd
since discussions had already been under way with other companies prior to the Oct PR,the 1st phase of any jv had already been completed by Oct
that 1st phase might take 6-9 of the usual 18 months- but is the part of the process that is most susceptible to being speeded up.
the rest of the process has to be carefully tailored (and in the biotech arena includes 3 major groups who have to coordinate-scientists, businessmen and lawyers, plus a back and forth with the decision makers -the board) because failure to carefully tailor the jv can easily be disastrous to NNLX
btw it can take 9-18 months just for companies tor revamp their websites in-house
the all too common temptation of the junior company is to yield to the unrelenting big boy pressure to accept a bad shark deal negotiated by the bigger company-the money boys -but yielding to that pressure almost always results in disaster-so NNLX has to be patient in the negotiating process-it has taken me many years to negotiate deals on occasion due to interference by outside parties etc-where there were no 'national security and emergency priority' considerations. In the profit sector,there is always a game in the 'everybody wants a bigger share of the pie' human consortium.
so it takes time -the commodity penny traders seem to be most short on
for newbies coming into biotechs you have to be aware of this- and its true it has already been forever as the friend who got me into this in 2010 said when I initially resisted and said, "but biotechs take forever"
proof of that is that in most pennies somebody who had been w a stock for 5 years would be the grandpa of the board-but many here have been w NNLX longer than I-though i started this board as an alternative to the basher boards
from a biotech perspective the company has made substantial and real progress in the last years both in its product -patents and distribution agreements -and as i said a yoy revenue increase of 4.08 times-most companies would kill for that
but impatience being what it is - urged on by bashers and other mutants- it is never enough for most in the penny world
and thus-especially because low pennies are a shorters paradise-especially 'no info' co's (which i and most long investors never trawl with-most stick to SEC reporting or at least otc current co's-and many SEC reporting are now listed as OTC current) - pps usually falls until these companies progress/product comes to the attention of a broader pool of investors-and i've previously discussed that process at great length
but from what I've seen NNLX's unusual for pennies holy grail has been to cut costs to achieve net income without toxic financing or badly negotiated shark deals
ironically-the current situation-w considerable product and revenue progress-has yielded the lowest historical pps=which is where the gold is if you believe NNLX will successfully transition to net income
HUBBARD, Ohio--(BUSINESS WIRE)--
NanoLogix Inc. (NNLX), an innovative biotechnology company in Northeastern Ohio announces that it is configuring its N-Assay Rapid diagnostic kits for both Ebola Virus and Enterovirus detection and identification. NanoLogix CEO Bret Barnhizer stated, “The Company has been aware of the virus detection capabilities of the technology since the N-Assay development. Viruses viewed as public health concerns prior to Ebola and Enterovirus were Influenza, the common cold, and HIV, none of which have an immediate or near-immediate threat of mortality. Until recently, NanoLogix has been focused solely on the use of their N-Assay kit for bacteria detection and identification. Now, with the recent outbreaks of both Ebola and Enterovirus there is an immediate need for configuration of the N-Assay for viruses. NanoLogix facilities are not designed for work on viruses, for this specific project we are seeking a corporate partner with the facilities necessary to bring the new N-Assay (V) to the market as quickly as possible. We consider this a matter of national security and an emergency priority. We are in discussions with potential partners, positioned with strong ties to the US government, who understand the serious threat these viruses represent.”
the biotech world is outside my normal frame of reference and has its own set of exigencies-e.g., may have a speeded up jv process due to "national security and an emergency priority' considerations.
Also when I speak of 18 months,that includes an initial period of time when companies come to each others attention-often without direct contact- they often know the companies in their field but may not know startup companies-and usually do their own private getting to know dd of the other company BEFORE even making a decision to approach the other company (think of the reasons why this is so-including cloak and dagger/MI-6 )-and remember we are still doing dd on NNLX after many years but without the monetary resources etc often employed by companies in their dd
since discussions had already been under way with other companies prior to the Oct PR,the 1st phase of any jv had already been completed by Oct
that 1st phase might take 6-9 of the usual 18 months- but is the part of the process that is most susceptible to being speeded up.
the rest of the process has to be carefully tailored (and in the biotech arena includes 3 major groups who have to coordinate-scientists, businessmen and lawyers, plus a back and forth with the decision makers -the board) because failure to carefully tailor the jv can easily be disastrous to NNLX
btw it can take 9-18 months just for companies tor revamp their websites in-house
the all too common temptation of the junior company is to yield to the unrelenting big boy pressure to accept a bad shark deal negotiated by the bigger company-the money boys -but yielding to that pressure almost always results in disaster-so NNLX has to be patient in the negotiating process-it has taken me many years to negotiate deals on occasion due to interference by outside parties etc-where there were no 'national security and emergency priority' considerations. In the profit sector,there is always a game in the 'everybody wants a bigger share of the pie' human consortium.
so it takes time -the commodity penny traders seem to be most short on
for newbies coming into biotechs you have to be aware of this- and its true it has already been forever as the friend who got me into this in 2010 said when I initially resisted and said, "but biotechs take forever"
proof of that is that in most pennies somebody who had been w a stock for 5 years would be the grandpa of the board-but many here have been w NNLX longer than I-though i started this board as an alternative to the basher boards
from a biotech perspective the company has made substantial and real progress in the last years both in its product -patents and distribution agreements -and as i said a yoy revenue increase of 4.08 times-most companies would kill for that
but impatience being what it is - urged on by bashers and other mutants- it is never enough for most in the penny world
and thus-especially because low pennies are a shorters paradise-especially 'no info' co's (which i and most long investors never trawl with-most stick to SEC reporting or at least otc current co's-and many SEC reporting are now listed as OTC current) - pps usually falls until these companies progress/product comes to the attention of a broader pool of investors-and i've previously discussed that process at great length
but from what I've seen NNLX's unusual for pennies holy grail has been to cut costs to achieve net income without toxic financing or badly negotiated shark deals
ironically-the current situation-w considerable product and revenue progress-has yielded the lowest historical pps=which is where the gold is if you believe NNLX will successfully transition to net income
